The estimated Net Worth of Eric R. Mortensen is at least $149 Thousand dollars as of 14 August 2019. Eric Mortensen owns over 5,000 units of Cytosorbents Corp stock worth over $148,932 and over the last 7 years Eric sold CTSO stock worth over $0.
Sign up
Eric Mortensen CTSO stock SEC Form 4 insiders trading
Eric has made over 2 trades of the Cytosorbents Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently Eric exercised 5,000 units of CTSO stock worth $22,500 on 14 August 2019.
The largest trade Eric's ever made was exercising 5,000 units of Cytosorbents Corp stock on 14 August 2019 worth over $22,500. On average, Eric trades about 1,250 units every 133 days since 2017. As of 14 August 2019 Eric still owns at least 148,932 units of Cytosorbents Corp stock.
You can see the complete history of Eric Mortensen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Eric Mortensen's mailing address?
Eric's mailing address filed with the SEC is C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION, NJ, 08852.
Insiders trading at Cytosorbents Corp
Over the last 16 years, insiders at Cytosorbents Corp have traded over $1,216,453 worth of Cytosorbents Corp stock and bought 832,447 units worth $1,058,402 . The most active insiders traders include James T. Gunton, Al Kraus, and Phillip P. Chan. On average, Cytosorbents Corp executives and independent directors trade stock every 34 days with the average trade being worth of $41,883. The most recent stock trade was executed by Alan D. Sobel on 13 December 2023, trading 22,557 units of CTSO stock currently worth $30,001.
What does Cytosorbents Corp do?
cytosorbents (nasdaq: ctso) cytosorbents corporation is a leader in critical care immunotherapy, specializing in blood purification. its flagship product, cytosorb® is approved in the european union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. these are conditions where the risk of death is extremely high, yet no effective treatments exist. cytosorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. cytosorbents' purification technologies are based on biocompatible, highly porous polymer beads
What does Cytosorbents Corp's logo look like?
Complete history of Eric Mortensen stock trades at Cytosorbents Corp
Cytosorbents Corp executives and stock owners
Cytosorbents Corp executives and other stock owners filed with the SEC include:
-
Phillip Chan,
President, Chief Executive Officer, Director -
Vincent Capponi,
Chief Operating Officer -
Kathleen Bloch,
Chief Financial Officer -
Dr. Phillip P. Chan,
CEO & Director -
Vincent J. Capponi M.S., MS,
Pres & COO -
Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D.,
Chief Medical Officer -
Kathleen P. Bloch CPA, M.B.A., MBA, CPA,
CFO & Sec. -
Al Kraus,
Independent Non-Executive Chairman of the Board -
Alan Sobel,
Independent Director -
Edward Jones,
Independent Director -
Michael Bator,
Independent Director -
Dr. Robert H. Bartlett,
Co-Chairman of Cardiac Surgery Advisory Board & Consultant -
Christopher Cramer,
VP of Bus. Devel. -
Dr. Christian Steiner M.D.,
Exec. VP of Sales & Marketing -
Terri Anne Powers M.B.A.,
VP of Investor Relations & Corp. Communications -
Peter J Mariani,
Chief Financial Officer -
Eric R. Mortensen,
Chief Medical Officer -
Robert Hawes Bartlett,
Chief Medical Officer -
Investment Fund, Lp Njtc,
10% owner -
Joseph Rubin,
Director -
Ronald Berger,
Interim CFO -
James T. Gunton,
Director -
Efthymios Deliargyris,
Chief Medical Officer -
Jiny Kim,
Director